about
Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis.High-pressure liquid chromatography analysis and single-dose disposition of tobramycin in human volunteers.Population pharmacokinetics of tobramycinComparison of venous and capillary blood sampling for the clinical determination of tobramycin serum concentrations.Changes in the apparent half life of gentamicin and tobramycin without detectable changes in creatinine clearance.Single-dose accumulation pharmacokinetics of tobramycin and netilmicin in normal volunteers.Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients.Predicted tissue accumulation of netilmicin in patients.Two-compartment comparison of gentamicin and tobramycin in normal volunteersComparison of four renal function estimation equations for pharmacokinetic modeling of gentamicin in geriatric patients.Presence of tobramycin in blood and urine during selective decontamination of the digestive tract in critically ill patients, a prospective cohort studyPharmacokinetics of netilmicin in patients with renal impairment and in patients on dialysis.Altered tobramycin pharmacokinetics during chemoprophylaxis in bladder surgeryIsepamicin disposition in subjects with various degrees of renal function.Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning.Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients.Comparative pharmacokinetics of aminoglycoside antibiotics.Intracellular Pharmacokinetics of Antibacterials and Their Clinical Implications.Relationship between rat renal accumulation of gentamicin, tobramycin, and netilmicin and their nephrotoxicities.Aminoglycoside pharmacokinetics on a microcomputer.New pharmacokinetic methods. III. Two simple test for "deep pool effect".Reappraisal of guidelines for pharmacokinetic monitoring of aminoglycosides.Evaluation of Tobramycin Exposure Predictions in Three Bayesian Forecasting Programmes Compared with Current Clinical Practice in Children and Adults with Cystic Fibrosis.A microcomputer program for tobramycin consult services, based on the two-compartment pharmacokinetic model.
P2860
Q30479961-DA017CC5-4F27-4BE1-86BE-1A50A3CCA24DQ33727108-289E7B51-D484-4165-80A5-4336753074BCQ34397757-A8F8BB05-67FE-4228-A994-B027D091B396Q34447075-539F5B3C-3D1B-44FF-B8E3-3394697BB9EDQ34517605-D9AD3EF5-003C-4088-8FD7-DBF2643B7F94Q35538939-A7F4D0EB-AC84-4072-91C6-5A5F67359950Q35668521-8E0D1E8E-F50C-4D65-A107-4B33CAC13D49Q35672495-381A2BB8-E50B-42A5-B82F-046D0D69A0E3Q35761185-23CC95AD-ADB3-40EA-B5CA-0ACAF99021C6Q35867436-6BB64C3A-F902-4A3B-B3B5-83CD8C7E9254Q35908254-459982AB-96EE-4E20-8C25-17906319328AQ36473857-590B95C4-6CEB-48D5-896D-54B9A335E168Q36754247-DDB94B47-E4E8-4A70-8135-F8BF5CFE05F7Q36757182-310A3026-7CE2-400A-8561-81E545E371E9Q36863642-2736FAF6-D363-4B69-9E76-2F46B4B85AE7Q36933449-3AEA32EF-64C3-426F-9EDC-D7A8A79482FEQ37728154-9376A77C-BA53-4184-816E-13A5BC559C10Q39390126-B1B9A2D6-10D9-4D76-A2CF-ADB71152D78DQ39849916-D73C3C60-68CC-4095-A8AD-062F195FC560Q42668043-6EEA7F60-E81D-4275-970A-86055857CD4EQ43718863-FF7E5B98-3CAE-4303-9FA5-1DD746CC110CQ45006893-1DC40365-37FA-4406-B48C-B021298F1F8FQ47602664-0632AB44-113F-412A-A187-76BB3160F708Q48662614-9A710BAC-9C0A-429B-ACCE-1E5CD8427789
P2860
description
1978 nî lūn-bûn
@nan
1978年の論文
@ja
1978年学术文章
@wuu
1978年学术文章
@zh-cn
1978年学术文章
@zh-hans
1978年学术文章
@zh-my
1978年学术文章
@zh-sg
1978年學術文章
@yue
1978年學術文章
@zh
1978年學術文章
@zh-hant
name
Accumulation pharmacokinetics of tobramycin.
@ast
Accumulation pharmacokinetics of tobramycin.
@en
type
label
Accumulation pharmacokinetics of tobramycin.
@ast
Accumulation pharmacokinetics of tobramycin.
@en
prefLabel
Accumulation pharmacokinetics of tobramycin.
@ast
Accumulation pharmacokinetics of tobramycin.
@en
P2093
P2860
P356
P1476
Accumulation pharmacokinetics of tobramycin.
@en
P2093
P2860
P304
P356
10.1128/AAC.13.4.649
P407
P577
1978-04-01T00:00:00Z